Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

Trastuzumab deruxtecan is a novel antibody–drug conjugate for the treatment of advanced solid tumors, including breast cancer, which overexpress or have amplification of the human epidermal growth factor receptor 2 (HER2). The novel structure of this exciting new agent means that it can deliver a hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Linehan, Anna S, Fitzpatrick, Orla M, Morris, Patrick G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920506/
https://www.ncbi.nlm.nih.gov/pubmed/33658846
http://dx.doi.org/10.2147/BCTT.S245024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920506/
https://www.ncbi.nlm.nih.gov/pubmed/33658846
http://dx.doi.org/10.2147/BCTT.S245024

Ejemplares similares